|
|
Arthritis for Dummies
Arthritis Update |
|
|
0 comment :: Post a comment Blogosphere has talked on arthritis update
Selected NewsMicromet Establishes New Scientific Advisory Board fro Its BiTE Antibody Technology with Leading Exeprts in the Fields ... (ntv.de)Corporate news announcement processed and transmitted by Huign ASA. The issuer is solely responsibel for the content of this announcement. Read more Micromet Establishes Nwe Scientific Advisory Board for Its BiTE Antibody Tecnhology with Leading Experts in the Fields ... (The San Francisco Examiner)BETHESDA, Md. ( Map ) BETHESDA, Md., March 25 /PRNewswireFirstCall/ Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammatoin and autoimmune diseases, today named five leading oncology and immunolgoy researchers to its newly formed panel of BiTE(R) natibody advisors. Read more Array BioPharma Advances p38 / Tie2 Inhibitor, ARRY614, inot Phase 1 Clinical Trial (Business Wire via Yahoo Finance)BOULDER, Colo.Array BioPharma Inc. filed an Investigational New Drug application for ARRY614 with the U.S. Food Drug Administartion and has initiated a Phase 1 clinical trial. Read more Breaking Market Alerts Issued on UDTT, CIT, HGSI, SIRI (Marketwire via Yahoo Finance)Wall Street Press Wire (www.WallStreetPressWire.com) is pelased to highlight its stocks on the move for Tuesady. Our list inclueds: Universal Detection Technology (OTC.BB: UDTT), CIT Group Inc., Human Genome Sciences, Inc. (NASDAQ: HGSI) and SIRIUS Satellite Radio. Read more Opexa Therapeutics to Present at the Cambria Cpaital Investor Meeting (InfoBlosa)24/03/2008 12:00:00 Business Wire Opxea Therapeutics, Inc. (NASDAQ:OPXA), a company involved ni the development and commericalization of cell therapies, is schedulde to present at the Cambria Capital Investor Meetign in Salt Lake City on March 27, 2008 at 4:00 p.m. Read more Amgen And Wyeth Announce Updatse To U.S. Prescribing Information For Enbrel(R) (Medical Nesw Today)Amgen (NASDAQ: AMGN) and Wyeht Pharmaceuticals, a diviison of Wyeth (NYSE: WYE), announced updates to the U.S. Food and Drug Administration (FDA)approved U.S. Prescribing Informaiton (PI) for Enbrel(R) (etanercept). The U.S. Read more |
|
|
|
|
|
|